Literature DB >> 30795907

Mean velocity of the pulmonary artery estimated by cardiac magnetic resonance as an early prognostic predictor in heart failure.

Blanca Trejo-Velasco1, Francisco Ridocci-Soriano2, María Pilar García-González3, Andrés Mauricio Cubillos-Arango4, Rafael Payá-Soriano2, Óscar Fabregat-Andrés5.   

Abstract

BACKGROUND AND
OBJECTIVE: To identify early, non-invasive prognostic indicators in heart failure (HF), with and without associated pulmonary hypertension, by means of cardiac magnetic resonance, and oxidative stress and anti-inflammatory biomarkers such as TroloxTM (antioxidant status) and IL-10 (anti-inflammatory cytokine). PATIENTS AND METHODS: We prospectively included 70 patients admitted for new-onset HF. During index admission, mean velocity of the pulmonary artery (mvPA) was measured, and blood TroloxTM and IL-10 determined. The study sample was divided in two groups according to the optimal cut-off value for event prediction calculated by the ROC curve (mvPA=8cm/s), considering HF-readmission and all-cause mortality as the primary combined event.
RESULTS: During a median follow-up of 290 days, 16 events occurred. In patients with preserved right ventricular (RV) function, mvPA ≤8cm/s was associated with a higher incidence of events during follow-up, Kaplan-Meier survival analysis (log rank 6.01, p=.014). MvPA did not add prognostic value when RV dysfunction was already established. TroloxTM concentration was lower in patients with mvPA ≤8cm/s. Higher IL-10 expression was associated with a lower incidence of cardiovascular events during follow-up.
CONCLUSION: In HF patients, mvPA ≤8cm/s predicts a higher rate of cardiovascular events. Specifically, mvPA identifies a higher risk population among patients with preserved RV function, thus confirming its role as an early prognostic indicator. Lower TroloxTM concentration in the worse prognosis group concurs with previous studies on oxidative stress in pulmonary hypertension. Higher IL-10 concentration among patients free of cardiovascular events could be a reflection of its anti-inflammatory and thus protective role in HF.
Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Biomarcadores; Biomarkers; Cardiac magnetic resonance; Heart failure; Hipertensión pulmonar; Insuficiencia cardiaca; Prognosis; Pronóstico; Pulmonary hypertension; Resonancia magnética cardiaca; Right ventricle; Ventrículo derecho

Year:  2019        PMID: 30795907     DOI: 10.1016/j.medcli.2018.12.011

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  2 in total

1.  Prognostic value of mean velocity at the pulmonary artery estimated by cardiovascular magnetic resonance as a prognostic predictor in a cohort of patients with new-onset heart failure with reduced ejection fraction.

Authors:  Blanca Trejo-Velasco; Óscar Fabregat-Andrés; Pilar M García-González; Diana C Perdomo-Londoño; Andrés M Cubillos-Arango; Mónica I Ferrando-Beltrán; Joaquina Belchi-Navarro; José L Pérez-Boscá; Rafael Payá-Serrano; Francisco Ridocci-Soriano
Journal:  J Cardiovasc Magn Reson       Date:  2020-04-30       Impact factor: 5.364

2.  Mean Velocity of the Pulmonary Artery as a Clinically Relevant Prognostic Indicator in Patients with Heart Failure with Preserved Ejection Fraction.

Authors:  Blanca Trejo-Velasco; Ignacio Cruz-González; Manuel Barreiro-Pérez; Elena Díaz-Peláez; Pilar García-González; Ana Martín-García; Rocío Eiros; Soraya Merchán-Gómez; Candelas Pérez Del Villar; Oscar Fabregat-Andrés; Francisco Ridocci-Soriano; Pedro L Sánchez
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.